DiamiR Biosciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
DiamiR Biosciences - overview
Established
1998
Location
-, NJ, US
Primary Industry
Healthcare
About
Based in New Jersey, US, and founded in 1998 by Kira Sheinerman and Samuil Umansky, DiamiR LLC, doing business as DiamiR Biosciences operates as a molecular diagnostics company that offers targeted diagnostics for brain health, offering early detection and monitoring of neurodegenerative and neurodevelopmental disorders. The firm employs brain-enriched microRNA biomarkers in blood plasma that enable screening, diagnosis, and treatment monitoring, aiding in clinical trial enrollment and disease progression tracking. DiamiR addresses clinical needs in brain health diagnostics through their lead product, CogniMIR™, which targets early detection of mild cognitive impairment and Alzheimer’s disease.
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Diagnostic Equipment
Website
www.diamirbio.com/
Verticals
HealthTech
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.